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Abstract. 
 
The integrin 
 
a
 
9
 
b
 
1 has been shown to be 
widely expressed on smooth muscle and epithelial cells, 
and to mediate adhesion to the extracellular matrix 
proteins osteopontin and tenascin-C. We have found 
that the peptide sequence this integrin recognizes in
tenascin-C is highly homologous to the sequence recog-
nized by the closely related integrin 
 
a
 
4
 
b
 
1, in the induc-
ible endothelial ligand, vascular cell adhesion mole-
cule-1 (VCAM-1). We therefore sought to determine 
whether 
 
a
 
9
 
b
 
1 also recognizes VCAM-1, and whether 
any such interaction would be biologically significant. 
In this report, we demonstrate that 
 
a
 
9
 
b
 
1 mediates sta-
ble cell adhesion to recombinant VCAM-1 and to 
VCAM-1 induced on human umbilical vein endothelial 
cells by tumor necrosis factor-
 
a
 
. Furthermore, we show 
that 
 
a
 
9
 
b
 
1 is highly and selectively expressed on neutro-
 
phils and is critical for neutrophil migration on VCAM-1 
and tenascin-C. Finally, 
 
a
 
9
 
b
 
1 and 
 
a
 
4 integrins contrib-
ute to neutrophil chemotaxis across activated endothe-
lial monolayers. These observations suggest a possible 
role for 
 
a
 
9
 
b
 
1/VCAM-1 interactions in extravasation of 
neutrophils at sites of acute inflammation.
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I
 
NTEGRINS
 
 are heterodimeric receptors for extracellular
matrix and cell surface counter-receptors which play
important roles in embryonic development, inflam-
mation, wound healing, and tumorigenesis (Hynes, 1987,
1992; Ruoslahti and Pierschbacher, 1987). Integrin ligand-
binding specificity is determined by structural features of
each subunit, but there is considerable ligand-binding
overlap among integrin heterodimers. One clue to ligand-
binding overlap has been the degree of sequence homol-
ogy among integrin 
 
a
 
 subunits. For example, the integrin 
 
a
 
subunits 
 
a
 
5, 
 
a
 
v, 
 
aIIb
 
, and 
 
a
 
8 are all closely related, and in-
tegrin heterodimers containing these 
 
a
 
 subunits recognize
ligands containing the peptide sequence arginine-glycine-
aspartic acid (Hynes, 1992; Schnapp et al., 1995). Similarly,
the 
 
a
 
m, 
 
a
 
L, and 
 
a
 
x subunits are highly homologous to one
another and recognize closely related immunoglobulin
family members as ligands (Hynes, 1992). We previously
cloned and sequenced the integrin 
 
a
 
9 subunit, and have
shown that it forms a single integrin heterodimer, 
 
a
 
9
 
b
 
1
(Palmer et al., 1993). The 
 
a
 
9 subunit cDNA sequence is
41% identical to the integrin 
 
a
 
4 subunit sequence, but
 
#
 
27% identical to any other integrin subunit, identifying
 
a
 
9 and 
 
a
 
4 as sole members of a subfamily of integrin 
 
a
 
subunits.
In an effort to understand the structural basis of 
 
a
 
9
 
b
 
1
ligand-binding in more detail, we recently mapped the
 
a
 
9
 
b
 
1 ligand-binding site in the extracellular matrix protein
tenascin-C (Yokosaki et al., 1994). 
 
a
 
9
 
b
 
1 binds to a single
exposed loop in the third fibronectin type III repeat of te-
nascin-C (B–C loop) to a minimal sequence EIDGIEL
(Schneider et al., 1998; Yokosaki et al., 1998). We noticed
that a critical portion of this sequence (IDG) is homolo-
gous to the tripeptide sequence IDS present in the previ-
ously mapped ligand-binding site for the 
 
a
 
4
 
b
 
1 ligand, vas-
cular cell adhesion molecule-1 (VCAM-1
 
1
 
; Clements et
al., 1994; Yokosaki et al., 1998). Therefore, we undertook
 
Address correspondence to Dean Sheppard, Lung Biology Center, UCSF
Box 0854, San Francisco, CA 94143. Tel.: (415) 206-5901. Fax: (415) 206-
4123. E-mail: deans@itsa.ucsf.edu
 
1. 
 
Abbreviations used in this paper:
 
 EGM, endothelial cell growth media;
FMLP, formyl-methionylleucylphenylalanine; HUVE, human umbilical
vein endothelial; ICAM, intercellular adhesion molecule; IFN, interferon;
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the current study to determine whether 
 
a
 
9
 
b
 
1 recognizes
VCAM-1 as a ligand and whether or not any such interac-
tion is biologically significant.
 
Materials and Methods
 
Reagents
 
BSA, formyl-methionylleucylphenylalanine (FMLP), and dextran were
purchased from Sigma Chemical Co. Recombinant human tumor necrosis
factor (TNF)-
 
a
 
, recombinant human interferon (IFN)-
 
g
 
 (specific activity
of 10
 
7
 
 U/mg), and recombinant interleukin 8 (IL-8) were obtained from
R&D Systems, Inc.
 
 
 
Fluorescent reagent, 2
 
9
 
,7
 
9
 
-bis-(carboxyethyl)-5,6-car-
boxy-fluorescein acetoxymethyl ester (BCECF-AM) was purchased from
Molecular Probes, Inc. A recombinant form of the third fibronectin type
III repeat of chicken tenascin-C (Prieto et al., 1993) containing alanine
substitution mutations within the RGD site (TNfn3RAA), was obtained
from Anita Prieto and Kathryn Crossin (Scripps Research Institute, La
Jolla, CA) and prepared in 
 
Escherichia coli
 
. A recombinant VCAM-1/IgG
chimera (Yednock et al., 1995) was produced in baculovirus as previously
described. Recombinant intercellular adhesion molecule-1 (ICAM-1)-C
 
k
 
fusion protein was a gift from B. Imhof (Centre Medicale Universitaire,
Geneva, Switzerland) to D. Erle (University of California, San Francisco,
CA). Ficoll-hypaque plus for isolation of neutrophils from venous blood
was purchased from Pharmacia Biotech, Inc. and used according to the
manufacturer’s specifications.
 
Antibodies, Cells, and Cell Culture
 
Mouse mAbs, Y9A2 against human 
 
a
 
9
 
b
 
1 (Wang et al., 1996) and
AN100226M (100226) against 
 
a
 
4 (Kent et al., 1995), were prepared as
previously described. Mouse mAbs, W6/32 against human MHC and IB4
against the integrin 
 
b
 
2 subunit, were prepared from hybridomas obtained
from American Type Tissue Collection. Mouse monoclonal antihuman
VCAM-1 (CD106) was purchased from R&D Systems. FITC-labeled
mouse monoclonal anti-CD16 antibody was purchased from Caltag. Hu-
man umbilical vein endothelial (HUVE) cells were purchased from
Clonetics and grown in endothelial cell growth media (EGM) containing
2% FBS, 10 ng/ml human recombinant EGF, 50 
 
m
 
g/ml gentamycin, 50 ng/
ml amphotericin B, 12 
 
m
 
g/ml bovine brain extract, and 1 
 
m
 
g/ml hydrocorti-
sone and were used between passage 3 and 10. 
 
a
 
9- and mock-transfected
SW480 and CHO cells were generated by transfection with the previously
described full-length 
 
a
 
9 expression plasmid pcDNAIneo
 
a
 
9 (Yokosaki et
al., 1994) or the empty vector pcDNAIneo (Invitrogen Corp.) by calcium
phosphate precipitation. Transfected cells were maintained in Dulbecco’s
minimal essential medium(DMEM) supplemented with 10% FCS and the
neomycin analogue G-418 (1 mg/ml; Life Technologies, Inc.). Both cell
lines continuously expressed high surface levels of 
 
a
 
9
 
b
 
1 as determined by
flow cytometry with Y9A2 (Yokosaki, 1996, 1998).
 
Flow Cytometry
 
Cultured cells were harvested by trypsinization and rinsed with PBS. Non-
specific binding was blocked with normal goat serum at 4
 
8
 
C for 10 min.
Cells were then incubated with primary antibodies (unconjugated or con-
jugated with FITC) for 20 min at 4
 
8
 
C, followed by secondary antibodies
conjugated with phycoerythrin (Chemicon International, Inc.). Between
incubations, cells were washed twice with PBS. The stained cells were re-
suspended in 100 
 
m
 
l of PBS and fluorescence was quantified on 5,000 cells
with a FACScan
 
®
 
 (Becton Dickinson and Co.).
 
Immunoprecipitation and Western Blotting
 
Cells were lysed in immunoprecipitation buffer (100 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM CaCl
 
2
 
, 1% Triton X-100, 0.1% SDS, and 0.1%
NP-40) supplemented with 10 
 
m
 
g/ml pepstatin (Sigma Chemical Co.), 10
 
m
 
g/ml leupeptin, 5 
 
m
 
g/ml aprotinin (Calbiochem-Novabiochem Corp.),
and 1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.). Human
neutrophils (10
 
7
 
) were incubated with 1 mM diisopropyl flurophosphate
(Sigma Chemical Co.) for 15 min before cell lysis. After preclearing with
protein G–Sepharose, the supernatant was incubated with primary anti-
body for 2 h at 4
 
8
 
C and immune complexes were captured by protein
G–Sepharose for 45 min at 4
 
8
 
C. The beads were washed five times, and
boiled in 2.5
 
3
 
 nonreducing Laemmli sample buffer, and samples were
separated by SDS-PAGE on 7.5% gels under reducing conditions and
transferred to Immobilon membranes. Membranes were blocked with 4%
casein, incubated with affinity-purified anti-
 
a
 
9 cytoplasmic domain antise-
rum 1057 (Palmer et al., 1993), and developed with luminol.
 
Cell Adhesion Assays
 
Wells of nontissue culture treated polystyrene 96-well flat bottomed mi-
crotiter plates (Nunc Inc.) were coated by incubation with 100 
 
m
 
l VCAM-
1/Ig or TNfn3RAA for 1 h at 37
 
8
 
C. After incubation, wells were washed
with PBS, then blocked with 1% BSA in DMEM at 37
 
8
 
C for 30 min. Con-
trol wells were filled with 1% BSA in DMEM. SW480 or CHO cells were
detached using trypsin/EDTA and resuspended in serum-free DMEM.
For blocking experiments, cells were incubated with 10 
 
m
 
g/ml Y9A2 and/
or 100226, for 15 min at 4
 
8
 
C before plating. The plates were centrifuged
(top side up) at 10 
 
g
 
 for 5 min before incubation for 1 h at 37
 
8
 
C in humidi-
fied 5% CO
 
2
 
. Nonadherent cells were removed by centrifugation (top side
down) at 48 
 
g
 
 for 5 min. Attached cells were fixed with 1% formaldehyde
and stained with 0.5% crystal violet, and the wells were washed with PBS.
The relative number of cells in each well was evaluated after solubilization
in 40 
 
m
 
l of 2% Triton X-100 by measuring the absorbance at 595 nm in a
microplate reader (Bio-Rad Laboratories). All determinations were car-
ried out in triplicate.
For adhesion assays on HUVE cells, confluent monolayers of HUVE
cells were prepared in 96-well plates in 250 
 
m
 
l of EGM with 2% FBS.
Plates were washed twice with serum-free DMEM, then stimulated for
24 h at 37
 
8
 
C with TNF-
 
a
 
 (3 ng/ml) or IFN-
 
g
 
 (3 ng/ml) in serum-free
DMEM. SW480 cells were detached using trypsin/EDTA and labeled
with 2 
 
m
 
M BCECF-AM at room temperature for 30 min. Then cells were
washed three times with serum-free DMEM and incubated with blocking
antibody, Y9A2 (10 
 
m
 
g/ml), 100226 (10 
 
m
 
g/ml), or combinations of these
antibodies for 15 min on ice. In some experiments, HUVE cells were incu-
bated with CD106 (5 
 
m
 
g/ml) for 15 min at 37
 
8
 
C. 50,000 cells in 200 
 
m
 
l of se-
rum-free DMEM were added to each well, and plates were centrifuged at
20 
 
g
 
 for 5 min, and covered with aluminum foil to prevent photobleaching.
Plates were then incubated for 60 min at 37
 
8
 
C in 5% CO
 
2
 
. After incuba-
tion, nonadherent cells were removed by washing twice with serum-free
DMEM. Finally, 200 
 
m
 
l of the same medium was added to each well, and
fluorescence was quantified with a fluorometer (Fluoroskan II; Lab-
systems) at excitation wavelength 485 nm and emission wavelength 538 nm.
The adherent ratio (%) was calculated as follows: (
 
fluorescence from ex-
perimental sample
 
 
 
2
 
 
 
fluorescence from negative control sample
 
) 
 
4
 
 
 
total
fluorescence added to chamber
 
. All determinations were carried out in
triplicate.
 
Neutrophil Migration Assays
 
Neutrophils were purified from human peripheral venous blood contain-
ing 20 U/ml of heparin.
 
 
 
Neutrophils were isolated by ficoll-hypaque den-
sity gradient centrifugation, followed by 3% dextran sedimentation
(Gresham et al., 1986). Erythrocytes were subjected to hypotonic lysis, re-
maining neutrophils were washed and resuspended in PBS. The isolated
neutrophils were 
 
.
 
95% pure and 
 
.
 
95% viable as assessed by Wright-
Giemsa staining and trypan blue exclusion, respectively. Cell migration
was analyzed essentially as described by Marks et al. (1991). In brief, glass
coverslips were placed in 35-mm culture dishes and incubated with 100 
 
m
 
l
serum-free media containing 10 
 
m
 
g/ml VCAM-1/Ig, 10 mg/ml TNfn3RAA,
and 5 mg/ml of ICAM-1 or 1% BSA for 60 min at 378C, washed, and then
incubated with 1% BSA for 30 min. Neutrophils were incubated with no
antibody, Y9A2 (10 mg/ml), 100226 (10 mg/ml), IB4 (20 mg/ml), or combi-
nations of antibodies for 15 min at 48C, and were then incubated for 10
min at 378C with or without 10 nM FMLP. 104 cells were plated onto the
coverslip area of each well and allowed to attach at 378C for 5 min. Dishes
were then placed on a videomicroscope stage and individual fields (2003)
were recorded for 3 min. Three different fields were examined in each
chamber. To count the number of migrating cells in a given field, outlines
were made of each cell. Cells were considered to have migrated when
both the leading edge and tail of the cell moved $7 mm from their initial
position. At least 40 neutrophils were analyzed per field and the ratio of
migrating to total cells was calculated.
Neutrophil Transmigration Assays
Transendothelial neutrophil migration was assessed as described by Coo-Taooka et al. p120ctn in Cadherin Function 415
per et al. (1995). HUVE cells were plated onto polycarbonate inserts
(Transwell, 6.5-mm diameter, 8-mm pore for 24-well plate; Costar Corp.)
in 200 ml of serum-containing EGM, and allowed to grow to confluence
over 72 h. 500 ml serum-free DMEM was added to the lower chamber of
each well. 24 h before addition of neutrophils, upper chambers were
washed twice with serum-free media and new medium with or without 3
ng/ml of TNF-a. Immediately before the addition of neutrophils, the up-
per chambers were washed twice with serum-free DMEM and medium in
the lower chamber was replaced with 500 ml serum-free DMEM or serum-
free DMEM with 10 nM FMLP or 50 ng/ml IL-8. In some experiments
HUVE cells were incubated with CD106 (5 mg/ml) at 378C for 15 min. Pu-
rified neutrophils were incubated with no antibody, Y9A2 (10 mg/ml),
100226 (10 mg/ml), IB4 (20 mg/ml), W6/32 (10 mg/ml), or combinations of
antibodies for 15 min at 48C, and 2 3 105 cells in 200 ml of media were
added to each upper chamber. After 3 h at 378C in 5% CO2, nonadherent
cells in the upper chamber were removed. Medium, including migrated
neutrophils from the lower chamber, was collected, the lower chamber
was rinsed several times to collect all the neutrophils that had transmi-
grated, and the absence of additional adherent neutrophils was confirmed
microscopically. The medium and all washes were pooled and resus-
pended, and cells were counted with a hemocytometer. All determina-
tions were carried out in duplicate and repeated at least twice.
Results
a9b1 Mediates Static Adhesion of Resting
a9-transfected SW480 Cells and CHO Cells
to VCAM-1
To determine whether VCAM-1 could function as a ligand
for a9b1, we performed cell adhesion assays with two dif-
ferent cell lines, SW480 and CHO, that had been stably
transfected with either an a9-expression plasmid or empty
vector. Both cell lines stably expressed a9b1 on the cell
surface as demonstrated by flow cytometry with the anti-
a9b1 antibody Y9A2 (Fig. 1, A and B). Adhesion assays
were performed on plates coated with either the known
a9b1 ligand, recombinant TNfn3RAA (Fig. 1, C and D),
or recombinant VCAM-1/Ig (Fig. 1, E and F). For both
cell lines, a9-transfectants adhered to both TNfn3 and to
VCAM-1 in a concentration-dependent manner, whereas
Figure 1. Adhesion of  a9- and
mock-transfected SW480 and
CHO cells to TNfn3RAA or
VCAM-1. Flow cytometric eval-
uation of cell surface expression
of integrin a9 on CHO cells (A),
or SW480 cells (B). Open peaks
represent fluorescence of mock-
transfected cells and shaded
peaks represent fluorescence of
a9-transfected cells stained with
anti-a9b1 antibody, Y9A2. a9- or
mock-transfected CHO (C and
E) or SW480 cells (D and F)
were added to 96-well plates
coated with a range of concen-
trations of TNfn3RAA (C and
D) or VCAM-1/Ig (E and F).
Cells were allowed to attach for
1 h, nonadherent cells were re-
moved by centrifugation, and
adherent cells were stained with
crystal violet and quantified by
measurement of absorbance at
595 nm. Data for a typical ex-
periment are shown and are ex-
pressed as the mean (1 SD) of
triplicate measurements for un-
treated  a9-transfected cells
(squares), untreated mock-
transfected cells (circles), a9-
transfected cells treated with
Y9A2 (10 mg/ml; diamonds),
and mock-transfected cells
treated with Y9A2 (10 mg/ml;
triangles). Similar results were
obtained in four separate exper-
iments.The Journal of Cell Biology, Volume 145, 1999 416
mock-transfectants did not adhere to either substrate. Ad-
hesion of each a9-transfected cell line was completely in-
hibited by the anti-a9b1 antibody, Y9A2, demonstrating
that this effect was mediated by a9b1.
a9b1 Mediates Adhesion to TNF-a–activated, but not 
to IFN-g–activated HUVE Cells, Via Interaction with 
Induced VCAM-1
To determine whether a9b1-mediated adhesion to
VCAM-1 was biologically significant, we next examined
the role of this integrin in adhesion of cells to resting
HUVE cells, and to HUVE cells that had been activated
by incubation with TNF-a (3 ng/ml), a well characterized
inducer of VCAM-1 expression, or IFN-g (3 ng/ml), a cy-
tokine that does not induce VCAM-1 expression. The ef-
fects of each cytokine on VCAM-1 expression under the
conditions used in these experiments were examined by
flow cytometry with anti–VCAM-1 antibody CD106 (Fig.
2, B–D). As expected, resting HUVE cells (Fig. 2 B) and
HUVE cells stimulated with IFN-g (Fig. 2 D) did not ex-
press detectable levels of VCAM-1, but VCAM-1 was dra-
matically induced by TNF-a (Fig. 2 C). All cell lines exam-
ined demonstrated baseline adhesion to resting HUVE
cells, and demonstrated a similar level of adhesion to
HUVE activated by IFN-g, and this baseline adhesion was
unaffected by anti-a9b1 antibody (Fig. 2 A). However,
only  a9-transfected cells demonstrated enhanced adhesion
to TNF-a–treated HUVE. This enhanced adhesion was re-
turned completely to basal levels by antibody to either
a9b1(Y9A2) or to VCAM-1 (CD106), demonstrating that
it was due to an interaction between a9b1 and VCAM-1.
a9b1 Is Expressed on Neutrophils
We have previously demonstrated that a9b1 is widely ex-
pressed on epithelial and smooth muscle cells (Palmer et al.,
1993), but expression on leukocytes has not been reported.
To determine whether a9b1 is expressed on cells likely to
encounter activated endothelial cells, we performed flow
cytometry on whole blood leukocytes with the a9b1 anti-
body Y9A2. We evaluated expression on neutrophils,
monocytes, and lymphocytes by gating on each population
separately, based on differential light scattering. From a
separate atopic donor we evaluated expression on eosino-
phils, which were separated from other leukocytes based
on light scattering and the absence of surface expression of
CD16. In parallel, we examined expression of the structur-
ally related integrin subunit, a4. a9b1 was not detected on
lymphocytes or eosinophils and was expressed at low lev-
els on monocytes (Fig. 3 A). In contrast, a9b1 was highly
and uniformly expressed on human neutrophils. As ex-
pected, a4 was highly expressed on lymphocytes, mono-
cytes, and eosinophils, but was also detected on neutro-
phils, albeit at considerably lower levels.
Expression of a9 on neutrophils was further confirmed
by immunoprecipitation with Y9A2 followed by Western
blotting with an affinity-purified antiserum raised against
Figure 2. Adhesion of  a9- or
mock-transfected SW480 cells to
HUVE cells. (A) Confluent
monolayers of HUVE cells were
incubated for 24 h with medium
alone (no activation), TNF-a (3
ng/ml), or IFN-g (3 ng/ml). Fluo-
rescently labeled a9- or mock-
transfected SW480 cells were al-
lowed to adhere to HUVE cell
monolayers for 60 min in the
presence or absence of the a9b1
blocking antibody Y9A2 (10 mg/
ml) or the VCAM-1 blocking an-
tibody CD106 (5 mg/ml). Nonad-
herent cells were removed by
gentle washing and the percent
of adherent cells was calculated
based on fluorescence. Data are
presented as the mean (1 SD) of
triplicate measurements. Similar
results were obtained in two sep-
arate experiments. Flow cyto-
metric evaluation of cell surface
expression of VCAM-1 on
HUVE cells treated with me-
dium alone (B), TNF-a (3 ng/ml;
C), or IFN-g (3 ng/ml; D). Open
peaks represent fluorescence of
unstained HUVE cells and
shaded peaks represent fluores-
cence of cells stained with the
anti–VCAM-1 antibody, CD106.Taooka et al. p120ctn in Cadherin Function 417
a unique portion of the a9 cytoplasmic domain. A band of
160 kD (appropriate molecular mass for a9) was detected
in lysate of human neutrophils after immunoprecipitation
with Y9A2, but not after immunoprecipitation with the
control antibody R6G9 (Fig. 3 B).
a9b1 Mediates Migration of FMLP-activated 
Neutrophils on TNfn3 or VCAM-1
To determine whether a9b1 expression on neutrophils
was biologically significant, we initially sought to examine
static adhesion of neutrophils to dishes coated with either
TNfn3RAA or VCAM-1. However, in the absence of anti-
bodies against b2 integrins, neutrophils avidly adhered to
all surfaces examined, and in the presence of b2 integrin
blocking antibodies, neutrophils could not be induced to
adhere to either VCAM-1 or TNfn3RAA by incubation
with MnCl2, FMLP, phorbol esters, or the b1 activating
antibody TS2/16 (data not shown). Therefore, we exam-
ined the possible role of a9b1 in another important neu-
Figure 3. Expression of a4 or a9
integrins on leukocytes. (A)
Whole blood leukocytes were
stained with control antibody
E7P6 that recognizes avb6, an
integrin not expressed on leuko-
cytes (unshaded peaks), Y9A2
against a9b1, or 100226 against
a4 (shaded peaks). Fluores-
cence of lymphocytes, neutro-
phils, eosinophils, and mono-
cytes were analyzed separately
by gating on each population on
the basis of a plot of forward
versus side scattering of light.
Fluorescence of eosinophils was
analyzed from separate atopic
donor by gating on eosinophils
based on light scattering and the
absence of expression CD16.
(B) Western blot with anti-a9
antiserum 1057 of lysates of hu-
man neutrophils that had been
immunoprecipitated with anti-
a9b1 antibody Y9A2 or the con-
trol antibody R6G9 against the
irrelevant integrin avb6 (lane
2). The expected molecular
mass of the a9 subunit (160 kD)
is shown by the lefthand arrow.
The position of molecular size
marker (kD) is shown to the
right.The Journal of Cell Biology, Volume 145, 1999 418
trophil function, cell migration. Migration was examined
by counting the numbers of individual neutrophils that mi-
grated on chambers coated with either TNfn3RAA or
VCAM-1 in the presence or absence of the activating ago-
nist FMLP (10 nM). In the absence of FMLP, very few
neutrophils migrated on either substrate (Fig. 4 A), and
antibodies against a9b1, a4, or b2 integrins had no effect.
In the presence of FMLP, neutrophil migration was signif-
icantly enhanced on TNfn3RAA, an effect that was abol-
ished by antibody against a9b1. FMLP also enhanced neu-
trophil migration on VCAM-1, and this effect was partially
inhibited by antibodies against a9b1 or a4, and completely
inhibited by the combination of both antibodies. These
data demonstrate a significant role for a9b1 in mediating
neutrophil migration on both substrates. Antibody against
b2 integrins had no effect on neutrophil migration on
FMLP-induced neutrophil migration on TNfn3RAA or
VCAM-1. However, as expected, antibody against b2 in-
hibited FMLP-induced migration on the b2 integrin ligand
ICAM-1, whereas antibodies against a9b1 or a4 had no ef-
fect (Fig. 4 B).
a9b1 Mediates Migration of Neutrophils through 
Activated HUVE Cell Monolayers
We next sought to determine whether the effect of a9b1
and a4 integrin(s) described above was relevant to an in
vitro model of neutrophil extravasation–migration across
endothelial monolayers. HUVE cells were grown to con-
fluence on the top side of permeable filter supports and in-
cubated in the presence or absence of TNF-a (3 ng/ml).
Purified neutrophils were added to the apical compart-
ment in the presence or absence of FMLP added to the
basal compartment. These studies were performed in the
absence of blocking antibodies, or in the presence of anti-
bodies against a9b1, a4, b2, VCAM-1, control antibody
against MHC, or combinations of these antibodies. As ex-
pected, in the absence of blocking antibodies, FMLP
greatly increased neutrophil migration into the bottom
compartment, and this effect was augmented by pretreat-
ment of HUVE cells with TNF-a (Fig. 5 A). No antibody
affected basal migration across unstimulated HUVE cells
or FMLP-induced migration across unstimulated HUVE
cells (Fig. 5 B). However, antibody against either a9b1 or
a4 inhibited the augmented migration induced by TNF-a.
Antibody against VCAM-1 was equally effective in inhib-
iting migration across TNF-a–treated HUVE cells, sug-
gesting that TNF-a augmented transmigration was medi-
ated by an interaction between a9b1 and a4 integrins and
VCAM-1. As previously reported, antibody against b2 in-
tegrins also partially inhibited transmigration in response
to FMLP, but this effect was surprisingly small. Essentially
identical results were obtained when IL-8 was used as a
chemoattractant in place of FMLP (data not shown).
Discussion
The results of the current study demonstrate that the in-
ducible endothelial cell immunoglobulin family member,
VCAM-1, is an effective ligand for the integrin a9b1. This
receptor–ligand interaction is sufficient to support adhe-
sion of a9-transfected cell lines to VCAM-1 and to TNF-
a–activated HUVE cells, an effect that is mediated by the
binding of a9b1 to VCAM-1. Furthermore, a9b1 is uni-
formly and specifically expressed on normal resting hu-
man neutrophils, and mediates both neutrophil migration
on a fragment of tenascin-C or VCAM-1 and transmigra-
tion of neutrophils across TNF-a–activated endothelial
monolayers. Together, these data suggest a previously un-
suspected role for a9b1 and VCAM-1 in extravasation of
neutrophils at sites of acute inflammation.
In addition to a9b1, we found detectable, albeit low, lev-
els of the structurally related integrin a4 subunit on resting
human neutrophils. This finding is consistent with several
previous reports of a4 expression on neutrophils from a
variety of species (Issekutz et al., 1996; Gao and Issekutz,
1997; Davenpeck et al., 1998). Although the level of ex-
pression of a4 we detected on human neutrophils was one
to two orders of magnitude lower than expression on eo-
sinophils, monocytes, and lymphocytes, this low level
expression appeared to be biologically significant, since
antibody against a4 partially inhibited migration of neu-
trophils on VCAM-1 and migration across TNF-activated
endothelial monolayers. Recently, a4b1 has been shown
Figure 4. Neutrophil migration on VCAM-1 or TNfn3RAA.
Neutrophils were allowed to migrate on glass coverslips coated
with: (A) 1% BSA or TNfn3RAA (10 mg/ml); or (B) VCAM-1
(10 mg/ml) or ICAM-1 (5 mg/ml), for 3 min in the presence or ab-
sence of FMLP (10 nM), and in the presence of: no antibody;
a9b1 antibody, Y9A2 (10 mg/ml); a4 antibody, 100226 (10 mg/ml);
antibody IB4 (20 mg/ml); or the combination of these antibodies.
The percentage of migrating cells was determined by analyzing
$40 cells from each of three microscopic fields, and is expressed
as the mean (1 SD) of triplicate values from two separate exper-
iments.Taooka et al. p120ctn in Cadherin Function 419
to mediate both neutrophil adhesion to VCAM-1 (Daven-
peck et al., 1998) and neutrophil transmigration across fi-
broblast monolayers (Gao and Issekutz, 1997). As ex-
pected, a4 integrins did not contribute to migration on
TNfn3RAA, since this fragment of tenascin is not a ligand
for either a4 integrin.
Adhesion of activated neutrophils to endothelial cells at
sites of inflammation is well known to require the partici-
pation of integrins sharing the b2 subunit (Arfors et al.,
1987) which bind to two other members of the immuno-
globulin family expressed on endothelial cells, ICAM-1
(Marlin and Springer, 1987; Diamond et al., 1990) and
ICAM-2 (Staunton et al., 1989). ICAM-1 is constitutively
expressed on many epithelia, but expression is dramati-
cally induced by a variety of inflammatory stimuli, includ-
ing TNF-a. Our data do not address the role of a9b1 or a4
integrins in stable adhesion of neutrophils, since we were
not able to maintain adhesion of these cells to any sub-
strate in the presence of b2 integrin blocking antibodies.
This effect could be due to a critical role of these integrins
in adhesion or to an inhibitory signaling pathway through
which antibody-mediated ligation of b2 integrins inhibits
the function of other integrins, such as a9b1. However, the
mechanisms underlying the subsequent steps in neutrophil
extravasation, including detachment from sites of initial
adhesion and subsequent migration across the endothelial
cell surface and components of the underlying extracellu-
lar matrix, are not as well understood. The data in this
manuscript suggest, at least in the model system used,
that a9b1 and a4 integrins are likely to play important
roles. Both integrins could contribute to migration across
VCAM-1 expressing endothelial cells and shared ligands
such as osteopontin (Smith et al., 1996; Bayless et al.,
1998), and a9b1 could be critical for migration across te-
nascin-C that is present outside the vasculature at sites of
inflammation (Erickson, 1993).
A role for b2 integrin–independent processes in neutro-
phil extravasation in vivo has been suggested by several
sets of observations, including studies of neutrophil ex-
travasation into the liver in response to endotoxin (Essani
et al., 1997) and neutrophil migration into the alveolar
spaces of the lung in response to intratracheal instillation
of live bacteria (Doerschuk et al., 1990). Recent studies
demonstrating neutrophil extravasation into the lungs and
peritoneal cavity in b2 integrin knockout mice also dem-
onstrate the importance of mechanisms independent of b2
integrins (Mizgerd et al., 1997). The extent to which these
events are mediated by a9b1 and/or a4 integrins needs to
be determined from in vivo studies. We have recently suc-
ceeded in generating mice expressing a null mutation in
the a9 subunit gene, but these mice die within 10 d of birth
(unpublished observation). However, the development of
bone marrow chimeras from this line should allow us to di-
rectly examine these questions.
In addition to the expression on neutrophils described in
this report, a9b1 is widely expressed on muscle cells, sur-
face epithelial cells, and hepatocytes (Palmer et al., 1993).
It is unclear what role, if any, interactions with VCAM-1
might have at these sites. VCAM-1 has also been reported
to be expressed on muscle cells under various conditions
(Rosen et al., 1992; Sheppard et al., 1994), so it is conceiv-
able that a9b1/VCAM-1 interactions may be biologically
significant in muscle as well. Such an effect could explain
the apparent contradiction between reports, based on anti-
body inhibition, that a4b1/VCAM-1 binding plays a criti-
cal role in myotube formation (Rosen et al., 1992) and the
normal muscle development of a4 knockout cells in chi-
meric mice (Yang et al., 1996), if the a4 knockout led to a
developmentally regulated increase in a9b1 expression.
In summary, we have identified VCAM-1 as a novel and
biologically significant ligand for the integrin a9b1, have
demonstrated that this integrin is expressed on neutrophils
and mediates neutrophil migration on two relevant ligands
and neutrophil transmigration across activated endothelial
monolayers. These findings support a role for a9b1/
VCAM-1 interactions in extravasation of neutrophils at
sites of inflammation.
Figure 5. Transmigration of neutrophils across activated HUVE
cell monolayers. Purified human neutrophils that had been incu-
bated with no antibody or antibody to a9b1 (Y9A2, 10 mg/ml),
a4b1 (100226, 10 mg/ml), b2 (IB4, 20 mg/ml), a combination of
these antibodies, or human MHC (W6/32, 10 mg/ml) were added
to the top chambers above microporous chambers containing
confluent monolayers of HUVE cells that had been incubated
with (A) or without TNF-a (3 ng/ml; B) for 24 h. DMEM con-
taining FMLP (10 nM) or DMEM alone was added to the bottom
chamber. After 3 h at 378C in 5% CO2, neutrophils that had mi-
grated across the monolayer were collected from the bottom
chamber and counted. In additional chambers, untreated neutro-
phils were added to HUVE cells that had been preincubated for
15 min with antibody to VCAM-1 (CD106, 5 mg/ml). Data are ex-
pressed as the mean (1 SD) of quadruplicate measurements
from two separate experiments.The Journal of Cell Biology, Volume 145, 1999 420
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